UK

The Medicines and Healthcare products Regulatory Agency (MHRA) is the primary regulatory authority in the United Kingdom, responsible for overseeing the safety, quality, and efficacy of medicines, medical devices, diagnostics, and digital health technologies. The MHRA operates under a consolidated legal framework that includes the Human Medicines Regulations 2012, the Medical Devices Regulations 2002 (as amended), and the Medicines Act 1968, supplemented by post-Brexit legislation introduced through the Medicines and Medical Devices Act 2021. Since the UK's departure from the European Union, the MHRA functions as a fully independent regulator and no longer participates in the EMA centralised procedure, though it maintains mutual recognition arrangements with select international partners including a framework agreement with the European Medicines Agency for information sharing and collaborative scientific work.

For medicines, applicants may pursue a national marketing authorisation through the MHRA's national procedure, a Great Britain-specific route, or the International Recognition Procedure (IRP), which allows approvals granted by recognised regulators such as the EMA, FDA, Health Canada, or TGA to be used as the basis for a UK authorisation, significantly reducing review timelines. The Common Technical Document (CTD) format is the accepted dossier standard across all product types. Medical devices and in vitro diagnostics require registration on the MHRA's Device Registration System and, for higher-risk classifications, a UK Approved Body conformity assessment; CE marks issued before 30 June 2023 were accepted under transitional provisions, but the new UK Conformity Assessed (UKCA) marking framework is being phased in progressively through 2025 and beyond. Digital health tools, including Software as a Medical Device (SaMD), are assessed under the same device classification principles with additional guidance published by NICE and NHS England. A UK Responsible Person or UK Established Entity is required for all overseas manufacturers placing products on the Great Britain market, while Northern Ireland retains alignment with EU MDR and IVDR frameworks under the Windsor Framework.

Public procurement of health products in the UK is structured across several interconnected national and devolved bodies. NHS England, together with NHS Supply Chain, serves as the primary centralised procurement vehicle for the English National Health Service, consolidating purchasing of medicines, devices, and consumables through national frameworks, category towers, and long-term agreements. The NHS Commercial Framework and the Crown Commercial Service (CCS) Health Category provide additional contracting routes for digital health and managed service solutions. Scotland, Wales, and Northern Ireland operate their own procurement agencies, namely NHS National Services Scotland (NSS), NHS Wales Shared Services Partnership (NWSSP), and the Business Services Organisation (BSO) respectively, each conducting independent tender exercises while frequently collaborating on pan-UK horizon scanning and joint evaluations coordinated through the four-nation Chief Pharmaceutical Officers' network. Pricing and reimbursement for branded medicines is governed by the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), and all medicines and technologies seeking routine NHS commissioning are subject to health technology assessment (HTA) by the National Institute for Health and Care Excellence (NICE) in England, the Scottish Medicines Consortium (SMC), or the All Wales Medicines Strategy Group (AWMSG).

The private healthcare sector in the UK, encompassing independent hospitals, private clinics, and retail pharmacy chains, represents a distinct procurement channel operating outside NHS frameworks, with purchasing decisions made at the organisational or group level through direct supplier agreements and GPO-style consortia. The UK does not rely materially on donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi for domestic health product supply, as it is a high-income country and a net donor to these mechanisms rather than a recipient. However, UK-based manufacturers and distributors frequently engage with these channels for export and global health purposes. Local manufacturing preference is not a formal statutory requirement in UK procurement law; however, the NHS Long Term Plan and the subsequent Life Sciences Vision 2021 articulate strategic policy support for domestic manufacturing resilience, accelerated access partnerships, and Innovative Medicines Fund arrangements that can provide faster NHS entry for transformative therapies pending full NICE appraisal.